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See related article in 2003;126:
232-9. Can an immunologic attack on cells expressing donor human leuko-cyte antigens (HLAs) contribute to human allograft valve (AV)deterioration? Not so, say the supporters of a mechanical mecha-nism of failure.1 They interpret anti-HLA antibodies in AV recip-ients2-4 as irrelevant epiphenomena that result from mechanicalfailure liberating soluble HLA from the AV to stimulate the im-
mune system.5 Unfortunately, this hypothesis is inconsistent with the appearance of
anti-HLA antibodies within 30 days of implantation.3 Nevertheless, until recently,
a pathogenic role for the immune response in AV degeneration was unproved
because a link with functional outcomes was lacking.
The report by Baskett and colleagues6 in the July 2003 issue, together with
similar conclusions from Dignan and associates,7 provides convincing evidence that
a significant component of AV degeneration is immunologic. What is the mecha-
nism linking AV deterioration and HLA mismatch between donor and recipient?
The same relationship is shown in extensive multicenter studies of solid organ
transplants between 0 to 6 antigen HLA mismatches and solid organ graft failure
rates.8 The accepted underlying mechanism is an allogeneic T-cell response initiated
by recognition of nonself HLA-DR on graft dendritic and endothelial cells, followed
by an amplification phase against HLA-A and HLA-B molecules in addition to
HLA-DR on most parenchymal cells.9 Such an immune response causing destruc-
tion of HLA-positive cells in the AV provides the most plausible explanation for the
observation in the studies by Baskett and colleagues6 and Dignan and associates.7
Apart from antigen presentation, it is unlikely that the HLA system mediates any
nonimmunologic function that could contribute to mechanical AV degeneration. Of
interest is a tissue culture study reported by Hoekstra and coworkers10 predicting
that mismatch between HLA-DR on human AV endothelial cells and lymphocytes
would produce an allogeneic response potentially capable of damaging the AV.
An HLA mismatch effect is likely to be exaggerated by enhanced AV immuno-
genicity after shorter incubation times7 and in younger recipients who have height-
ened immune reactivity.7,11,12 Younger age is a very important determinant of
decreased durability of the aortic AV used for aortic valve replacement.12 The
10-year actuarial freedom from reoperation for structural degeneration in the 20
years and younger age group at implantation was 47% compared with 93%, 95%,
and 96% in those aged 21 to 40, 41 to 60, and more than 60 years, respectively.12
Looking for an HLA mismatch effect is inherently difficult because a paired
donor and recipient will by chance have few of the 6 possible antigens in common.
HLA-A and HLA-B are extremely polymorphic, and even the HLA-DR group
consists of 16 discrete antigens.13 There have been 2 studies of similar design to that
of Baskett and colleagues6 that fail to show a significant effect of HLA mismatch on
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AV longevity.14,15 Relatively short periods of observation,
longer incubation times after harvest reducing AV immu-
nogenicity, small numbers in one study, and older recipient
cohorts are likely to have biased toward a negative result.
More studies of similar design to that of Baskett and col-
leagues focusing on younger and larger recipient cohorts,
fresher AVs, and longer mean periods of 5 to 10 years’
surveillance are needed.
There is widespread interest in reducing the recipient’s
response to donor HLA in the hope that this will delay AV
deterioration, particularly in young adults and children.
There are no clinical data to suggest that immune suppres-
sion protects the AV from immunologic injury. Ideally,
regimens such as low-dose cyclosporine16 given to protect
the right-sided allograft after a Ross procedure should be
subjected to trial. It is unlikely there exists enough enthu-
siasm for such trials in young cohorts because of the poten-
tial toxicities of the current antiproliferative, cytotoxic, and
calcineurin-inhibiting agents. Animal studies are not prom-
ising, suggesting that the AV might be protected from
immune destruction only for as long as combination im-
mune suppression is continued (unpublished data).17
Could an immune response to the AV be minimized by
using organ-sharing networks to direct HLA and ABO-
typed AV in tissue banks to the best-matched recipient?
Although this strategy is highly successful and economi-
cally sound for renal allografts, consideration of the size of
the AV pool required, donor availability, standardization of
AV preparation, and the costs of typing, harvesting, and
transport would have to be balanced against the benefits of
reduced reoperation rates in a younger population in which
the AV is the preferred replacement.
Modification of the AV to reduce immunogenicity is an
exciting and evolving area. The pivotal question underlying
this endeavor is the nature of the AV cells that display
HLA-DR so provocatively to the recipients’ T cells. Den-
dritic cells, also known as “professional” antigen-presenting
cells are the most effective exponents of alloantigen pre-
sentation.18 Endothelial cells, also constitutively expressing
HLA-DR, might carry out similar functions under the spe-
cial conditions of cell culture or once exposed to inflamma-
tory cytokines.10 Thus far, searches of the human aortic
valve have found few dendritic cells, but the vascular sub-
population of dendritic cells might not express the expected
surface antigens.19 Modifications of the AV designed to
deplete antigen-presenting cells might also damage stromal
cells and fibroblasts, with adverse effects on function.
Much research with some clinical application has been
directed to tissue-engineered valves. In the hope of avoiding
the immune response, decellularized AVs (both aortic and
pulmonary) have been clinically implanted. Elkins and col-
leagues20 have reported 2 years’ clinical experience with
right-sided implants using AVs treated with the SynerGraft
antigen reduction process (Cryolife Inc, Kennesaw, Ga) to
encourage recellularization in vivo. An alternative direction
used seeding of a decellularized pulmonary AV in vitro with
autologous adult endothelial cells before implantation.21
Early promising results from these pioneering studies
provide some hope that we might not have to resort to HLA
matching or immune suppression. The immune system
might not prove easy to bypass, however. The low incidence
of anti-HLA antibodies reported by Elkins and associates22
in recipients of decellularized AVs is reassuring but never-
theless raises a note of caution because these antibodies
might not be a sensitive marker for the alloreactive cells that
are likely to be the actual agents of AV cell injury.3
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